Menu

Search

  |   Science

Menu

  |   Science

Search

Cancer Cure 2019: Less Popular Treatment - Thermal Ablation - to be Improved by Israeli Company for Precise 'Burning' of Tumors

Photo by: Marco Verch (CC BY 2.0 [https://creativecommons.org/licenses/by/2.0/]) via Flickr.com

A biotech company from Israel is currently working on improving a lesser popular cancer treatment while many other scientists and researchers work on a potential cure for the disease. People might now have heard much about thermal ablation but TechsoMed wants to improve this procedure for a more precise burning of a cancerous tumor.

The National Cancer Institute defines thermal ablation as, “A procedure using heat to remove tissue or a part of the body, or destroy its function.” While it is not a complete cure for cancer, it could be a significant treatment as it targets tumors and removes it from the body by burning it. However, according to a report from the Jerusalem Post, this treatment is far from being perfect that inspired the development of TechsoMed’s BioTrace technology.

At present, one of the thermal ablation’s setbacks is the fact that physicians will have to wait 24 hours after the procedure was done to determine whether or not they completely removed the cancerous tumor. This is where BioTrace promises to help. TechsoMed’s innovation is being described as “the world’s first real-time monitoring and control systems for the ablation procedure” that practically describes how it will improve thermal ablation treatments.

With improved imaging tech and the use of artificial intelligence, physicians will have the ability to monitor the scope of ablation they have done while they are doing it. No more waiting for an entire day to see if the cancer treatment procedure was successful.

As of the time of reporting, the Israeli company has seen significant progress in developing BioTrace for improved cancer treatments. The imaging technology has reportedly been successfully tested in preclinical and clinical trials on at least 54 patients in Mayo Clinic in the United States, in the University of Tokyo Hospital in Japan, and in Sheba Medical Center in Israel.

Development of BioTrace will reportedly continue for the next 12 months. The company is hoping that the cancer treatment technology will be allowed to be added in hospital facilities within a year.

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

July 2 15:00 UTC Released

DKCurrency Reserves

Actual

449.6 Stale

Forecast

Previous

451.7 Stale

July 2 13:45 UTC Released

USISM NY Biz Conditions

Actual

50 %

Forecast

Previous

48.6 %

January 31 00:00 UTC 771368771368m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 771368771368m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 783188783188m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 771368771368m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 783188783188m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 771368771368m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 771368771368m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 771368771368m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.